Blood test may predict liver cancer recurrence and guide immunotherapy
NCT ID NCT07350824
First seen Jan 20, 2026 · Last updated Apr 29, 2026 · Updated 9 times
Summary
This study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. About 276 adults with liver cancer who had surgery or ablation will be followed. The goal is to see if this test can also help decide who might benefit from additional immunotherapy treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MINIMAL RESIDUAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Division of Hepato-Pancreato-Biliary Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.